TFE3 and ovarian carcinoma: Identification of selective utilization of SHMT2 alternative promoter by the combination of HIFα and TFE3 in cisplatin-resistant ovarian cancer cells in the current study further strengthen the complicated interlinkage between hypoxia and SHMT2.